Endometrial cancer · 12 regimens
Cost vs Efficacy · 1 point
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Cisplatin and Ifosfamide Variant #01 | — | R 13 954 | 21d | — | 48.0 mo | 3 | R 41 861 PFS proxy | 1 |
Cisplatin and Epirubicin Variant #01 | — | R 2 911 | 21d | — | — | 4 | R 11 646 PFS proxy | 1 |
Epirubicin and Paclitaxel (EP) Variant #01 | — | R 2 715 | 21d | — | — | 6 | R 16 290 PFS proxy | 1 |
Carboplatin and Doxorubicin Variant #01 | — | R 1 789 | 21d | — | — | 4 | R 7 154 PFS proxy | 1 |
Cisplatin and Doxorubicin Variant #01 | — | R 1 434 | 21d | — | — | 6 | R 8 601 PFS proxy | 1 |
Carboplatin and Paclitaxel (CP) Variant #02 | — | R 1 025 | 21d | — | — | 18 | R 18 445 PFS proxy | 1 |
Cisplatin and RT Variant #01 | — | R 588 | 49d | ~28.0 mo | — | ~1 | ~R 588 PFS proxy · indirect | 8 |
Placebo Partial | — | — | — | ~10.2 mo | ~41.1 mo | — | — | 20 |
Radiation therapy N/A - radiation | — | — | 49d | — | — | — | — | 3 |
Whole abdominal radiation (WAI) Variant #01 | — | — | — | — | 24.0 mo | — | — | 1 |
Observation Partial | — | — | — | ~20.4 mo | ~38.6 mo | — | — | 4 |
CIM Partial | — | — | — | — | — | — | — | — |
12 of 12 regimens shown